ReviewCureus2025
Scientific Advances in Neural Regeneration After Spinal Cord Injury.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitochondrial-Inflammatory Axis Dysregulation Triggers Disulfidptosis and the Multifaceted Protective Mechanism of Bisphenol A Following Spinal Cord Injury.Molecular neurobiology · 2026Article
- The Interplay Between Neuromodulation and Stem Cell Therapy for Sensory-Motor Neuroplasticity After Spinal Cord Injury: A Perspective View.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating condition that results in loss of motor and sensory function, morbidity, and severe dependence. Neural regeneration, which refers to the regrowth or repair of nerve tissue or cells, holds promise as a therapeutic approach for SCI. This narrative review explores the current state of neural regeneration for SCI treatment, including endogenous neuroprotection, neuroplasticity, neuroremediation, and cell-based therapies. The review is based on a search of literature from the past 20 years, conducted via databases including PubMed and Google Scholar. While many of the studies show promising results, the majority are preclinical, highlighting the need for randomized clinical trials (RCTs) to evaluate the effectiveness of these therapies in humans. Among the different therapeutic approaches, cell-based therapies, particularly the use of neural stem cells, have shown the most promising results in promoting neural regeneration and functional recovery in animal models and human trials. Therefore, neural stem cell transplantation is considered the most useful treatment method for SCI. However, further research is needed to optimize the transplantation procedure, improve cell survival, and enhance functional outcomes in patients with SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.